Everything below concerns WADA prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
=== Writing === Shonda Rhimes said in an interview that the fifth season will begin only a few days after the events in the fourth-season finale. She stated that the fifth season will see Olivia and Fitz the only people standing in a single piece, as she said "The world had been fairly blown apart for everybody except Olivia and Fitz. Everybody else was in a fairly blown apart place ... We pick up right there in that environment and we see what happens next." Rhimes continued talking about Cyrus and Mellie and their situation of not being in the White House anymore. Rhimes also confirmed that "the reconstitution" of Team OPA would happen in the fifth season, as Rhimes revealed in an interview with TVLine, as she explained that the Gladiator conceit was sidelined a bit in the fourth season to instead "healing" Olivia. She noted that "a lot of times it was just Huck and Quinn gladiating by themselves. And that wasn’t the same dynamic."
The Jammu–Baramulla line of the Northern Railways is the only major railway line in Jammu and Kashmir. Its completion integrates the Kashmir Valley into India’s national rail grid and provides a direct rail link from other parts of India to the region. The line comprises Chenab Rail Bridge, the highest railway bridge in the world, and Anji Khad Bridge, the only cable-stayed railway bridge in India. The Udhampur-Srinagar-Baramulla Rail Link, a 272 km broad-gauge line that connects the Kashmir Valley to mainland India, achieved completion in December 2024 with the Reasi-Katra section (17 km), which features the Chenab Rail Bridge. The Banihal-Baramulla segment (118 km), among others, is electrified. The Jammu railway division, established in January 2025, oversees 742 km of operational tracks. It manages routes such as Pathankot-Jammu-Udhampur-Srinagar-Baramulla, Bhogpur Sirwal-Pathankot, Batala-Pathankot, and Pathankot-Joginder Nagar. The division oversees the operation of Vande Bharat Express trains between Jammu and Srinagar.
Vitamin A is a fat-soluble vitamin that is an essential nutrient. The term "vitamin A" encompasses a group of chemically related organic compounds that includes retinol, retinyl esters, and several provitamin (precursor) carotenoids, most notably β-carotene (beta-carotene). Vitamin A has multiple functions: growth during embryo development, maintaining the immune system, and healthy vision. For aiding vision specifically, it combines with the protein opsin to form rhodopsin, the light-absorbing molecule necessary for both low-light (scotopic vision) and color vision. Vitamin A occurs as two principal forms in foods: 1) retinoids, found in animal-sourced foods, either as retinol or bound to a fatty acid to become a retinyl ester, and 2) the carotenoids α-carotene (alpha-carotene), β-carotene, γ-carotene (gamma-carotene), and the xanthophyll beta-cryptoxanthin (all of which contain β-ionone rings) that function as provitamin A in herbivore and omnivore animals which possess the enzymes that cleave and convert provitamin carotenoids to retinol. Some carnivore species lack this enzyme. The other carotenoids do not have retinoid activity. Dietary retinol is absorbed from the digestive tract via passive diffusion. Unlike retinol, β-carotene is taken up by enterocytes by the membrane transporter protein scavenger receptor B1 (SCARB1), which is upregulated in times of vitamin A deficiency (VAD). Retinol is stored in lipid droplets in the liver.
=== Russell indices in Japan === Russell/Nomura equity indices for Japan (calculated with Nomura Securities Co., Ltd.) offer free-float adjusted broad market or style benchmarks for investors in that country.
==== MeSH D06.472.734 – pituitary hormones ==== MeSH D06.472.734.525 – pituitary hormones, anterior MeSH D06.472.734.525.343 – gonadotropins, pituitary MeSH D06.472.734.525.343.288 – follicle stimulating hormone MeSH D06.472.734.525.343.288.500 – follicle stimulating hormone, beta subunit MeSH D06.472.734.525.343.288.625 – follicle stimulating hormone, human MeSH D06.472.734.525.343.288.750 – glycoprotein hormones, alpha subunit MeSH D06.472.734.525.343.463 – luteinizing hormone MeSH D06.472.734.525.343.463.249 – glycoprotein hormones, alpha subunit MeSH D06.472.734.525.343.463.500 – luteinizing hormone, beta subunit MeSH D06.472.734.525.343.583 – menotropins MeSH D06.472.734.525.343.583.500 – urofollitropin MeSH D06.472.734.525.343.773 – prolactin MeSH D06.472.734.525.425 – growth hormone MeSH D06.472.734.525.425.875 – human growth hormone MeSH D06.472.734.525.690 – pro-opiomelanocortin MeSH D06.472.734.525.690.130 – corticotropin MeSH D06.472.734.525.690.130.050 – alpha-msh MeSH D06.472.734.525.690.130.200 – cosyntropin MeSH D06.472.734.525.690.480 – lipotropin MeSH D06.472.734.525.690.583 – melanocyte-stimulating hormones MeSH D06.472.734.525.690.583.050 – alpha-msh MeSH D06.472.734.525.690.583.075 – beta-msh MeSH D06.472.734.525.690.583.115 – gamma-msh MeSH D06.472.734.525.883 – thyrotropin MeSH D06.472.734.525.883.249 – glycoprotein hormones, alpha subunit MeSH D06.472.734.525.883.500 – thyrotropin, beta subunit MeSH D06.472.734.692 – pituitary hormones, posterior MeSH D06.472.734.692.433 – oxytocin MeSH D06.472.734.692.781 – vasopressins MeSH D06.472.734.692.781.100 – argipressin MeSH D06.472.734.692.781.100.250 – deamino arginine vasopressin MeSH D06.472.734.692.781.400 – lypressin MeSH D06.472.734.692.781.400.350 – felypressin MeSH D06.472.734.692.781.700 – ornipressin MeSH D06.472.734.692.881 – vasotocin
Sources: en.wikipedia.org
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. It acts against interleukin 31 (IL-31), which is a cytokine involved in causing itchiness (pruritus). Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016, and it was approved by the European Medicines Agency in 2017. Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.
International Cooperation/ Business Relations PRCL is actively collaborating and participating with its international counterparts in the field of insurance and reinsurance. This is being achieved under the aegis of Economic Cooperation Organization (ECO) with the object of reducing the outflow of Foreign Exchange and improving the standard of insurance and reinsurance services in the region. PRCL has been one of the pioneers and founder members of the Federation of Afro-Asian Insurers and Reinsurers (FAIR).
=== Osteoinduction === Osteoinduction involves the stimulation of osteoprogenitor cells to differentiate into osteoblasts that then begin new bone formation. The most widely studied type of osteoinductive cell mediators is bone morphogenetic proteins (BMPs). A bone graft material that is osteoconductive and osteoinductive will not only serve as a scaffold for currently existing osteoblasts but will also trigger the formation of new osteoblasts, theoretically promoting faster integration of the graft.
=== New defence team === In September 2024, Letby appointed a new defence lawyer, Mark McDonald. At a press conference in December 2024, McDonald said he was preparing fresh applications to both the Court of Appeal and the Criminal Cases Review Commission. He argued that the prosecution's lead expert witness, Dewi Evans, was unreliable, claiming that Evans had altered his views on how some infants had died. McDonald also said that several experts were producing reports on the infants' deaths without payment, and that two reports—relating to Children C and O—had concluded that there was no evidence of deliberate harm. Following the press conference, Evans rejected the criticisms, describing them as "unsubstantiated, unfounded, inaccurate". He said the only change in his evidence concerned the date of Child C's death, which he attributed to a clerical error by the prosecution. Some of Evans's post‑trial comments about the mechanisms of death differed from positions he had taken while giving evidence at trial. On 4 February 2025, Letby's legal team applied for her case to be reviewed as a potential miscarriage of justice. On the same day, findings from a panel of 14 international medical experts were released. Chaired by Shoo Lee, a retired neonatologist from the University of Toronto, the panel concluded that there was no medical evidence supporting claims that Letby had deliberately harmed or murdered infants at the Countess of Chester Hospital.
Heatley was able to develop a continuous extraction process. The penicillin-bearing solvent was easily separated from the liquid, as it floated on top, but now they encountered the problem that had stymied Craddock and Ridley: recovering the penicillin from the solvent. Heatley reasoned that if the penicillin could pass from water to solvent when the solution was acidic, maybe it would pass back again if the solution was alkaline. Florey told him to give it a try. Sodium hydroxide was added, and this method, which Heatley called "reverse extraction", was found to work. The next problem was how to extract the penicillin from the water. The usual means of extracting something from water were through evaporation or boiling, but this would destroy the penicillin. Chain hit upon the idea of freeze drying, a technique recently developed in Sweden. This enabled the water to be removed, resulting in a dry, brown powder. Heatley developed a penicillin assay using agar nutrient plates in which bacteria were seeded. Short glass cylinders containing the penicillin-bearing fluid to be tested were then placed on the nutrient plates and incubated for 12 to 16 hours at 37 °C. By then the fluid would have disappeared and the cylinder surrounded by a bacteria-free ring. The diameter of the ring indicated the strength of the penicillin. An Oxford unit was defined as the purity required to produce a 25 mm bacteria-free ring. It was an arbitrary measurement, as the chemistry was not yet known; the first research was conducted with solutions containing four or five Oxford units per milligram.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.